Development of ferroptosis use to treatment in oral squamous cell carcinoma

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K19217
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Osaka Dental University
• Principal Investigator: Ishikawa Hiroki 大阪歯科大学, 歯学部, 助教 (00825292)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 口腔癌 / フェロトーシス

Outline of Final Research Achievements

In this study, I investigated that ferroptosis inducing was useful in treatment strategy of oral squamous cell carcinoma. Erastin, which is ferroptosis inducer, induced ferroptosis in oral squamous cell carcinoma cells SAS and HSC-2. Furthermore, oral squamous cell carcinoma cells with mesenchymal condition by epithelial-mesenchymal transition was more sensitive to ferroptosis than normal condition.
These results suggested that ferroptosis inducing drugs may be useful to anti-cancer drug in treatment of advanced oral squamous cell carcinoma with invasion and metastasis.

Free Research Field

口腔癌

Academic Significance and Societal Importance of the Research Achievements

近年、口腔癌患者は増加傾向を辿っている。口腔癌の切除療法は審美面、摂食嚥下機能などの多様な日常生活機能の著しい障害を伴う。そのため、保存的な治療法の開発が望まれている中で、本研究の成果は口腔癌の保存的治療として活用される化学療法薬の新たな選択肢としてフェロトーシス誘導剤が有用となる可能性を示した。また、さらにその効果が進行癌に対して通常より感受性が高い可能性があることを示した。